Nanobiotix Current Valuation vs. Total Debt
| NANO Stock | EUR 3.29 0.10 3.13% |
For Nanobiotix profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Nanobiotix to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Nanobiotix SA utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Nanobiotix's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Nanobiotix SA over time as well as its relative position and ranking within its peers.
Nanobiotix |
Nanobiotix SA Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Nanobiotix's current stock value. Our valuation model uses many indicators to compare Nanobiotix value to that of its competitors to determine the firm's financial worth. Nanobiotix SA is rated top company in current valuation category among its peers. It also is rated top company in total debt category among its peers making up about 0.32 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for Nanobiotix SA is roughly 3.12 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Nanobiotix by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Nanobiotix's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Nanobiotix Current Valuation vs. Competition
Nanobiotix SA is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Drug Manufacturers - Major industry is now estimated at about 340.71 Million. Nanobiotix totals roughly 111.08 Million in current valuation claiming about 33% of equities under Drug Manufacturers - Major industry.
Nanobiotix Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Nanobiotix |
| = | 111.08 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Nanobiotix |
| = | 35.56 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
Nanobiotix Total Debt vs Competition
Nanobiotix SA is rated top company in total debt category among its peers. Total debt of Drug Manufacturers - Major industry is now estimated at about 263.94 Million. Nanobiotix retains roughly 35.56 Million in total debt claiming about 13% of equities under Drug Manufacturers - Major industry.
Nanobiotix Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Nanobiotix, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Nanobiotix will eventually generate negative long term returns. The profitability progress is the general direction of Nanobiotix's change in net profit over the period of time. It can combine multiple indicators of Nanobiotix, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.
Nanobiotix Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Nanobiotix. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Nanobiotix position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Nanobiotix's important profitability drivers and their relationship over time.
Use Nanobiotix in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nanobiotix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nanobiotix will appreciate offsetting losses from the drop in the long position's value.Nanobiotix Pair Trading
Nanobiotix SA Pair Trading Analysis
The ability to find closely correlated positions to Nanobiotix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nanobiotix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nanobiotix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nanobiotix SA to buy it.
The correlation of Nanobiotix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nanobiotix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nanobiotix SA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nanobiotix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Nanobiotix position
In addition to having Nanobiotix in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Corona Opportunity Thematic Idea Now
Corona Opportunity
Firms that are involved in some capacity in making products or providing services to the public to buttle the virus directly or indirectly. This also includes some defencive and contrarian stocks and ETFs that are managing to avoid the big market correction coused by coronavirus. The Corona Opportunity theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Corona Opportunity Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nanobiotix Stock
To fully project Nanobiotix's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Nanobiotix SA at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Nanobiotix's income statement, its balance sheet, and the statement of cash flows.